Semliki Forest virus vectors for gene therapy.

Area of Science:

• Virology
• Gene Therapy
• Immunology

Background:

• Semliki Forest virus (SFV) vectors are utilized for broad cell transduction and high transient protein expression.
• SFV vectors induce apoptosis in mammalian cells, a characteristic exploited in gene therapy.
• SFV vectors elicit a robust immune response against expressed proteins, offering potential anti-tumor effects.

Purpose of the Study:

• To explore the applications of Semliki Forest virus (SFV) vectors in gene therapy and cancer treatment.
• To investigate the potential of SFV vectors for producing therapeutic proteins and targeting tumors.
• To highlight advancements in SFV vector technology, including modified strains and liposome encapsulation.

Main Methods:

• Utilizing recombinant SFV particles, naked RNA, and plasmid DNA for gene delivery.
• Administering SFV particles via intratumoural injection.
• Encapsulating SFV particles into liposomes for targeted delivery.
• Developing novel SFV vectors with point mutations and avirulent strains.

Main Results:

• SFV vectors demonstrated broad transduction of mammalian and non-mammalian cells with high protein expression.
• Intratumoural injection of SFV particles led to significant tumour regression.
• Liposome-encapsulated SFV particles showed highly efficient tumor targeting.
• Modified SFV vectors expanded the range of applications.

Conclusions:

• SFV vectors are versatile tools for gene therapy, protein expression, and cancer treatment.
• SFV-mediated immune responses provide protection against tumor challenges.
• Advancements in SFV vector design and delivery systems enhance their therapeutic potential.